Physician profile
Douglas E Gladstone
NPI 1386660207
$41,835.94
in general payments reported to CMS, 2019-2025
17 companies · $5,633 in 2025
The $5,633 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,187 · 2020: $3,958 · 2021: $3,968 · 2022: $7,480 · 2023: $7,318 · 2024: $5,293 · 2025: $5,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $2,371 · Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,895.50 |
| Travel and Lodging | $2,370.82 |
| Food and Beverage | $1,977.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,080.83 | 2019-2025 | Calquence, Lumoxiti, Imfinzi |
| Adaptive Biotechnologies Corporation | $9,585.01 | 2020-2025 | Clonoseq |
| Janssen Biotech, INC. | $2,995.65 | 2019-2023 | Tecvayli |
| Incyte Corporation | $2,791.85 | 2021-2025 | |
| Genzyme Corporation | $2,078.00 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $1,899.28 | 2019-2020 | |
| Genentech USA, INC. | $1,674.49 | 2023-2025 | Polivy, Lunsumio |
| Abbvie INC. | $722.74 | 2020-2024 | |
| Beigene USA, INC. | $452.09 | 2023-2025 | Brukinsa |
| Beone Medicines USA, INC. | $263.11 | 2025 | Brukinsa |
| Kite Pharma, INC. | $120.54 | 2019-2024 | Yescarta |
| Adc Therapeutics America, INC. | $113.74 | 2023 | |
| Novartis Pharmaceuticals Corporation | $58.61 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Gladstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.